Evidence map›Paper›PMID 29855477›Full record

ArticleCell death & disease2018

Inhibition of the ER stress IRE1α inflammatory pathway protects against cell death in mitochondrial complex I mutant cells.

Meghan S Soustek, Eduardo Balsa, Joeva J Barrow, Mark Jedrychowski, Rutger Vogel, Jan Smeitink, Steve P Gygi, Pere Puigserver

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Intestinal NSD2 Aggravates Nonalcoholic Steatohepatitis Through Histone Modifications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Meghan S SoustekDepartment of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.
Eduardo BalsaDepartment of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.
Joeva J BarrowDepartment of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.
Mark JedrychowskiDepartment of Cell Biology, Harvard Medical School, Boston, MA, 02215, USA.
Rutger VogelRadboud Center for Mitochondrial Medicine, Radboud University Medical Center, Nijmegen, 6500HB, The Netherlands.
Jan SmeitinkRadboud Center for Mitochondrial Medicine, Radboud University Medical Center, Nijmegen, 6500HB, The Netherlands.
Steve P GygiDepartment of Cell Biology, Harvard Medical School, Boston, MA, 02215, USA.
Pere PuigserverDepartment of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA. Pere_Puigserver@dfci.harvard.edu.
Harvard University · USRadboud University Nijmegen · NLDana-Farber Cancer Institute · US

Funding

Metabolic Vulnerabilities in Melanoma TumorsR01CA181217 · NCI · DANA-FARBER CANCER INST · PI PUIGSERVER, PERE · 2014 to 2024
$3.7M
Metabolic and Bioenergetic Control in Mitochondrial DiseasesR01GM121452 · NIGMS · DANA-FARBER CANCER INST · PI PUIGSERVER, PERE · 2017 to 2020
$1.5M
YY1-mediated transcriptional control of thermogenic-secreted factors in brown fatF32DK105679 · NIDDK · DANA-FARBER CANCER INST · PI SOUSTEK, MEGHAN S · 2015 to 2017
$162k
Bromodomain Inhibitors Correct Bioenergetic Deficiency Caused by Mitochondrial Disease Complex MutationsF32GM121014 · NIGMS · DANA-FARBER CANCER INST · PI BARROW, JOEVA J. · 2017 to 2017
$59k
NCI NIH HHS R01 CA181217NIDDK NIH HHS F32 DK105679NIGMS NIH HHS F32 GM121014NIGMS NIH HHS R01 GM121452
6 · The paper itself

Abstract

Mitochondrial mutations cause bioenergetic defects associated with failures to use the electron transfer chain and oxidize substrates. These defects are exacerbated under energetic stress conditions and ultimately cause cell deterioration and death. However, little is known about cellular strategies that rescue mitochondrial stress failures and maintain cell survival under these conditions. Here, we have designed and performed a high-throughput chemical screen to identify small molecules that rescue human mitochondrial complex I mutations from energetic stress-induced cell death. The top positive hits were a series of sulfonylureas that efficiently maintain prolonged cell survival and growth under energetic stress conditions. The addition of galactose instead of glucose, to experimentally force mitochondrial respiration, triggered an initial ER stress response that was associated with IRE1α-dependent inflammatory signals including JNK and p38 MAP kinases in mutant cells. Sulfonylureas, similar to inhibition of IRE1α and p38 MAP kinase, potently blocked this ER stress inflammatory and cell death pathway and maintained viability and cell growth under severe energetic stress conditions. These studies reveal that sulfonylureas and specific inhibition of the IRE1α inflammatory pathway protect against cell death and can be used to rescue bioenergetic failures in mitochondrial complex I-mutated cells under stress conditions.

Indexed as

ApoptosisCytoprotectionEndoplasmic Reticulum StressElectron Transport Complex IEndoribonucleasesGalactoseHumansInflammationJNK Mitogen-Activated Protein KinasesMitochondriaMutationp38 Mitogen-Activated Protein KinasesProtein Serine-Threonine KinasesSulfonylurea CompoundsElectron Transport Complex IEndoribonucleasesERN1 protein, humanGalactoseglimepirideJNK Mitogen-Activated Protein Kinasesp38 Mitogen-Activated Protein KinasesProtein Serine-Threonine KinasesSulfonylurea Compounds

Identifiers

PMID29855477
PMCPMC5981317
OpenAlexW2806312996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.